FasL (soluble) (human), (recombinant)

Fas ligand



ALX-522-001-C010	10 µg		200.00 USD

ALX-522-001-3010	3x10 µg	SuperPack	420.00 USD
Bulk Request

Product Specification

Alternative Name:	APO-1L, CD95L, CD178, TNFSF 6

Concentration:	0.1mg/ml after reconstitution.

Endotoxin Content:	<0.1EU/µg purified protein (LAL test; Bio Whittaker).

MW:	~32kDa (non-glycosylated), ~35kDa (glycosylated) (SDS-PAGE).

Purity:	≥95% (SDS-PAGE)

Formulation:	Lyophilized. Contains PBS.

Biological Activity:	Kills Jurkat cells at concentrations of >10ng/ml in the absence of a cross-linker. Cross-linking enhancer (see Set Prod. No. ALX-850-014) increases the activity of rhsFasL approx. 50-fold. Attention: Results using sFasL may differ from those obtained with agonistic antibodies!

Specific Activity:	ED₅₀: 50ng/ml (A20 cells)

Source/Host:	Produced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG^®-tag. Glycosylation of rhsFasL is similar to that of natural human FasL.

Reconstitution:	Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.

Specificity:	Binds to human, mouse and rat Fas (CD95; APO-1).

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 6 months after receipt when stored at -20°C.

Handling:	After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Background / Technical Information:	UniProt ID P48023: FasL (human) AfCS Signaling Gateway ID A002830: FasL (mouse) FLAG is a registered trademark of Sigma-Aldrich Co.

Activity Assay analysis: Inhibition of FasL, Soluble (human) (rec.) (Prod. No. ALX-522-001)-mediated lysis. Fas (human):Fc (human) (rec.) (Prod. No. ALX-522-002) exerts its inhibitory activity in a concentration range of 0.5-5μg/ml in the presence of the enhancer (1μg/ml).

Please mouse over

Product Literature References

Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development: V. Labi, et al.; J. Exp. Med. 205, 641 (2008), Abstract; Full Text

Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy: C. Gajate & F. Mollinedo; J. Biol. Chem. 280, 11641 (2005), Abstract; Full Text

Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion: M. C. Michallet, et al.; Blood 102, 3719 (2004), Abstract;

The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF: A. Tardivel, et al.; Eur. J. Immunol. 34, 509 (2004), Abstract;

A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in: S. Klunker, et al.; J. Immunol. 171, 1078 (2003), Abstract; Full Text

BCR engagement induces Fas resistance in primary B cells in the absence of functional Bruton's tyrosine kinase: J.R. Tumang, et al.; J. Immunol. 168, 2712 (2002), Abstract;

Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia: M. Sata, et al.; J. Immunol. 166, 6964 (2001), Abstract;

Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway: D. Siegmund, et al.; J. Biol. Chem. 276, 32585 (2001), Abstract; Full Text

Mechanisms underlying neuronal death induced by chromogranin A-activated microglia: J. Ciesielski-Treska, et al.; J. Biol. Chem. 276, 13113 (2001), Abstract; Full Text

T cell costimulation by the TNF ligand BAFF: B. Huard, et al.; J. Immunol. 167, 6225 (2001), Abstract;

Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants: A.R. Thilenius, et al.; Eur. J. Immunol. 27, 1108 (1997), Abstract;

Characterization of Fas (Apo-1, CD95)-Fas ligand interaction: P. Schneider, et al.; J. Biol. Chem. 272, 18827 (1997), Abstract; Full Text